Business
Enanta Pharmaceuticals to Present Data for EDP-938, its Oral, Once-Daily, N-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2023
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"text","content":" WATERTOWN, Mass.--(BUSINESS WIRE)--\nEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections, today announced that data for EDP-938, its oral, once-daily, N-protein inhibitor in development for the treatment of respiratory syncytial virus (RSV), will be presented at IDWeek 2023 being held October 11 - 15, 2023 at the Boston Convention and Exhibition Center in Boston, MA.\n\n\nDate: Thursday, October 12, 2023\nTime: 12:15 - 1:30 PM ET\nAbstract Number: 923\nPoster Title: “EDP-938, A Respiratory Syncytial Virus Antiviral, Demonstrates a High Barrier to Resistance in a Human Challenge Study”\nSession Title: Virology: Treatment and Prevention of Viral Infections\nLocation: Boston Convention and Exhibition Center Poster Hall\nPresenter: Rachel Levene, Ph.D.\n\n\nFurther information about IDWeek 2023 can be found here.\n\n\nAbout Enanta Pharmaceuticals, Inc.\nEnanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).\n\n\nGlecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic hepatitis c virus infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET®.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230907333204/en/\n\nMedia and Investors Contact\nJennifer Viera\n617-744-3848\[email protected]\n\n\nSource: Enanta Pharmaceuticals, Inc.","length":3520,"tagName":"div"}]